UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Indiana 35-0470950 Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip ...

[APA Corporation Second-Quarter 2025 Results](index=1&type=section&id=APA%20Corporation%20Announces%20Second-Quarter%202025%20Financial%20and%20Operational%20Results) [Financial Highlights](index=1&type=section&id=Financial%20Highlights) APA Corporation reported Q2 2025 net income of $603 million ($1.67 diluted EPS), adjusted earnings of $313 million ($0.87 diluted EPS), and strong cash flow with $1.2 billion from operations and $1.3 billion adjusted EBITDAX Q2 2025 Key Financial Metrics | Metric | Amount (in millions) | | :--- | :--- | | Net Income (attributable to common stock) | $603 | | Diluted EPS | $1.67 | | Adjusted Earnings | $313 | | Adjusted Diluted EPS | $0.87 | | Net Cash Provided by Operating Activities | $1,200 | | Adjusted EBITDAX | $1,300 | [Operational Highlights](index=1&type=section&id=Operational%20Highlights) APA exceeded Q2 2025 production guidance with 465,000 BOE/day reported (394,000 adjusted), reduced Permian rig count while maintaining outlook, and expanded Egypt's footprint Q2 2025 Production | Metric | Volume (BOE/day) | | :--- | :--- | | Reported Production | 465,000 | | Adjusted Production | 394,000 | - Permian rig count reduced from **eight to six** due to drilling efficiencies, maintaining flat Permian volumes with fewer rigs[5](index=5&type=chunk)[7](index=7&type=chunk) - Egypt exceeded gas production guidance and secured presidential approval for **2 million additional acres**, expanding its footprint by over **35%**[4](index=4&type=chunk)[5](index=5&type=chunk) [Capital Allocation and Balance Sheet](index=2&type=section&id=Capital%20Allocation%20and%20Balance%20Sheet) APA returned $140 million to shareholders, reduced net debt by over $850 million (15%), and set a new long-term net debt target of $3 billion - Returned **$140 million** to shareholders through dividends and share repurchases[5](index=5&type=chunk)[9](index=9&type=chunk) - Reduced net debt by over **$850 million** (more than **15%**), supported by asset sales and Egypt working capital inflows[5](index=5&type=chunk)[9](index=9&type=chunk) - Initiated a new long-term net debt target of **$3 billion**, reflecting confidence in durable cash flows and investment-grade credit profile[10](index=10&type=chunk) [Strategic Initiatives](index=3&type=section&id=Strategic%20Initiatives) APA accelerated cost reduction targets to $350 million run-rate savings by 2026 and increased 2025 realized savings to $200 million, while GranMorgu project remains on track Updated Cost Reduction Targets | Metric | Previous Target | New Target | | :--- | :--- | :--- | | 3-Year Run-Rate Savings Goal | $350M by YE 2027 | $350M in 2026 | | 2025 Realized Savings | $130M | $200M | | 2025 Year-End Run-Rate Savings | $225M | $300M | - GranMorgu project in Suriname remains on schedule for first oil in **mid-2028**; 2025 capital guidance raised to **$275 million** for milestone payments, with no change to total project costs[13](index=13&type=chunk)[14](index=14&type=chunk) [Financial Statements and Supplemental Data](index=7&type=section&id=Financial%20Statements%20and%20Supplemental%20Data) [Statement of Consolidated Operations](index=7&type=section&id=Statement%20of%20Consolidated%20Operations) Q2 2025 total revenues decreased to $2.18 billion from $2.54 billion, while net income attributable to common stock increased to $603 million ($1.67 diluted EPS) Q2 2025 vs Q2 2024 Income Statement Highlights (in millions, except per share data) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Total Revenues | $2,178 | $2,543 | | Net Income Before Income Taxes | $1,028 | $928 | | Net Income Attributable to Common Stock | $603 | $541 | | Diluted EPS | $1.67 | $1.46 | [Production Information](index=8&type=section&id=Production%20Information) Q2 2025 total reported production decreased 2% to 465,078 BOE/day, with US down 4% and Egypt up 8% driven by gas volumes Q2 2025 Production by Region (BOE/day) | Region | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | United States | 289,902 | 303,416 | (4)% | | Egypt | 143,818 | 133,215 | 8% | | North Sea | 31,358 | 36,778 | (15)% | | **Total** | **465,078** | **473,409** | **(2)%** | [Adjusted Production Information](index=9&type=section&id=Adjusted%20Production%20Information) Q2 2025 adjusted production decreased 3% to 394,041 BOE/day, with US and North Sea declines offset by 11% growth in Egypt's adjusted volumes Q2 2025 Adjusted Production by Region (BOE/day) | Region | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | United States | 289,902 | 303,416 | (4)% | | Egypt | 72,781 | 65,296 | 11% | | North Sea | 31,358 | 36,778 | (15)% | | **Total** | **394,041** | **405,490** | **(3)%** | [Price Information](index=10&type=section&id=Price%20Information) APA realized lower Q2 2025 oil prices at $65.58/barrel (down from $82.28) but higher natural gas prices at $2.28/Mcf (up from $1.77) Average Realized Prices | Commodity | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Oil (per barrel) | $65.58 | $82.28 | | Natural Gas (per Mcf) | $2.28 | $1.77 | | NGL (per barrel) | $20.49 | $21.68 | [Supplemental Financial Information](index=11&type=section&id=Supplemental%20Financial%20Information) Q2 2025 net cash from operations was $1.18 billion, with total assets at $18.08 billion, total debt at $4.55 billion, and cash at $107 million [Summary Cash Flow Information](index=12&type=section&id=Summary%20Cash%20Flow%20Information) Q2 2025 net cash provided by operating activities was $1.18 billion, with net cash used in investing and financing activities Q2 2025 Cash Flow Summary (in millions) | Category | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $1,181 | $877 | | Net cash used in investing activities | $(95) | $(64) | | Net cash used in financing activities | $(1,046) | $(755) | [Summary Balance Sheet Information](index=12&type=section&id=Summary%20Balance%20Sheet%20Information) As of June 30, 2025, total assets were $18.08 billion, total debt was $4.55 billion, and APA shareholders' equity was $5.91 billion Balance Sheet Highlights (in millions) | Account | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $107 | $625 | | Total assets | $18,078 | $19,390 | | Current debt | $263 | $53 | | Long-term debt | $4,288 | $5,991 | | Total debt | $4,551 | $6,044 | | APA shareholders' equity | $5,905 | $5,280 | [Non-GAAP Reconciliations](index=13&type=section&id=Non-GAAP%20Reconciliations) This section reconciles GAAP to non-GAAP metrics, including Q2 2025 upstream capital investment of $648 million, free cash flow of $134 million, and adjusted EBITDAX of $1.3 billion [Reconciliation to Upstream capital investment](index=13&type=section&id=Reconciliation%20to%20Upstream%20capital%20investment) Q2 2025 total upstream capital investment was $648 million, a decrease from $827 million in the prior year - Total Upstream capital investment for Q2 2025 was **$648 million**, down from **$827 million** in Q2 2024[40](index=40&type=chunk) [Reconciliation to Free cash flow](index=13&type=section&id=Reconciliation%20to%20Free%20cash%20flow) Q2 2025 free cash flow was $134 million, an increase compared to $103 million in the prior-year quarter - Free cash flow for Q2 2025 was **$134 million**, compared to **$103 million** in Q2 2024[42](index=42&type=chunk) [Reconciliation to Adjusted EBITDAX](index=14&type=section&id=Reconciliation%20to%20Adjusted%20EBITDAX) Q2 2025 Adjusted EBITDAX was $1.3 billion, a decrease from $1.58 billion in the prior-year quarter - Adjusted EBITDAX for Q2 2025 was **$1,299 million**, compared to **$1,576 million** in Q2 2024[44](index=44&type=chunk) [Reconciliation to net debt](index=14&type=section&id=Reconciliation%20to%20net%20debt) Net debt as of June 30, 2025, was $4.44 billion, a significant reduction from $5.42 billion at year-end 2024 - Net debt as of June 30, 2025, was **$4,444 million**, a significant reduction from **$5,419 million** at the end of 2024[46](index=46&type=chunk) [Reconciliation to Adjusted earnings](index=15&type=section&id=Reconciliation%20to%20Adjusted%20earnings) Q2 2025 adjusted earnings were $313 million, or $0.87 per diluted share, after accounting for various adjustments Q2 2025 Adjusted Earnings Reconciliation | Metric | Amount (in millions) | Per Diluted Share | | :--- | :--- | :--- | | Net income attributable to common stock (GAAP) | $603 | $1.67 | | Adjustments (net) | $(290) | $(0.80) | | **Adjusted earnings (Non-GAAP)** | **$313** | **$0.87** |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-23621 MKS INC. (Exact name of registrant as specified in its charter) Massachusetts 04-2277512 (State or other jurisdiction (I.R.S. E ...

Table of Contents Commission File Number 0-16759 FIRST FINANCIAL CORPORATION (Exact name of registrant as specified in its charter) | Indiana | 35-1546989 | | --- | --- | | (State or other jurisdiction | (I.R.S. Employer | | incorporation or organization) | Identification No.) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended June 30, 2025 ☐ TRANSITION RE ...

[PART I - FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) This part details the company's financial performance, condition, and cash flows, along with management's analysis and market risk disclosures [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) The unaudited condensed consolidated financial statements for Avadel Pharmaceuticals plc for Q2 and H1 2025 and 2024 are presented, including income, comprehensive income, balance sheets, equity, cash flows, and detailed notes [Summary of Significant Accounting Policies](index=11&type=section&id=NOTE%201%3A%20Summary%20of%20Significant%20Accounting%20Policies) The company is a biopharmaceutical firm whose sole commercial product is LUMRYZ, an extended-release sodium oxybate for treating cataplexy or EDS in narcolepsy patients - LUMRYZ was approved by the FDA for adults with narcolepsy on **May 1, 2023**, and for pediatric patients (age 7+) on **October 16, 2024**[35](index=35&type=chunk) - The company has initiated a pivotal Phase 3 trial, REVITALYZ, to evaluate LUMRYZ for the treatment of Idiopathic Hypersomnia (IH)[37](index=37&type=chunk) - LUMRYZ was granted Orphan Drug Designation (ODD) by the FDA for the treatment of IH on **June 5, 2025**[37](index=37&type=chunk) [Revenue Recognition](index=14&type=section&id=NOTE%202%3A%20Revenue%20Recognition) All net product revenue for the reported periods is derived from U.S. sales of LUMRYZ, with sales highly concentrated among three customers Percentage of Total Gross Sales by Customer | Customer | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Caremark | 41% | 52% | 43% | 48% | | Accredo | 40% | 33% | 42% | 36% | | Optum | 19% | 15% | 15% | 16% | [Royalty Financing Obligation](index=17&type=section&id=NOTE%206%3A%20Royalty%20Financing%20Obligation) The company has a royalty financing obligation with RTW Investments, L.P. stemming from a $30 million tranche received in August 2023, requiring quarterly payments of 3.75% of worldwide LUMRYZ net product revenue until $75 million is repaid - The company received **$30 million** from RTW and must pay **3.75%** of worldwide LUMRYZ net revenue until a total of **$75 million** is repaid[64](index=64&type=chunk)[65](index=65&type=chunk) Royalty Financing Obligation Activity (in thousands) | Description | June 30, 2025 | | :--- | :--- | | Beginning Balance (Dec 31, 2024) | $37,139 | | Accretion of imputed interest | $4,593 | | Royalty payments made | $(3,859) | | Ending Balance (before current portion) | $37,873 | | Non-current Royalty financing obligation | $35,318 | - Interest expense related to the royalty financing obligation was **$2.4 million** for Q2 2025 and **$4.6 million** for the six months ended June 30, 2025[68](index=68&type=chunk) [Commitments and Contingencies](index=21&type=section&id=NOTE%2012%3A%20Commitments%20and%20Contingencies) This section details the extensive and complex litigation between Avadel and Jazz Pharmaceuticals, involving multiple patent infringement lawsuits and countersuits - In the 'First Jazz Complaint', a jury found Avadel infringed one Jazz patent (U.S. Patent No. 11147782) and awarded damages of **$234**, with a subsequent injunction largely reversed or vacated on appeal by the Federal Circuit in **May 2025**[98](index=98&type=chunk)[102](index=102&type=chunk) - Avadel successfully forced Jazz to delist its REMS Patent (U.S. Patent No. 8731963) from the Orange Book following a court order, which was affirmed on appeal in **February 2023**[93](index=93&type=chunk) - Jazz's lawsuit challenging the FDA's approval of LUMRYZ was dismissed, and the D.C. Court of Appeals affirmed the ruling in **June 2025**, upholding the FDA's approval[140](index=140&type=chunk)[141](index=141&type=chunk) - Avadel has filed its own lawsuits against Jazz, alleging infringement of its patents by Jazz's product XYWAV®, as well as claims of trade secret misappropriation, with these cases ongoing and trial dates set for **2025** and **2028**[120](index=120&type=chunk)[131](index=131&type=chunk)[132](index=132&type=chunk) Consolidated Statements of Income (Loss) Highlights (in thousands) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Net product revenue | $68,129 | $41,504 | $120,640 | $68,682 | | Gross profit | $61,763 | $38,716 | $108,697 | $64,372 | | Operating income (loss) | $8,884 | $(12,741) | $5,883 | $(38,776) | | Net income (loss) | $9,665 | $(13,822) | $4,745 | $(41,164) | | Net income (loss) per share - diluted | $0.10 | $(0.14) | $0.05 | $(0.44) | Consolidated Balance Sheet Highlights (in thousands) | Metric | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $63,402 | $51,371 | | Total current assets | $159,105 | $134,208 | | Total assets | $187,157 | $164,236 | | Total current liabilities | $57,065 | $48,834 | | Total liabilities | $96,448 | $90,388 | | Total shareholders' equity | $90,709 | $73,848 | Consolidated Statements of Cash Flows Highlights (in thousands) | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $4,465 | $(47,890) | | Net cash provided by investing activities | $4,063 | $31,937 | | Net cash provided by financing activities | $1,672 | $13,913 | | Net change in cash and cash equivalents | $12,031 | $(2,320) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=32&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's transition to profitability in Q2 2025, driven by LUMRYZ commercialization, highlighting revenue growth, stable operating expenses, and sufficient liquidity for the next twelve months - The company achieved profitability in Q2 2025 with a net income of **$9.7 million**, a significant turnaround from a net loss of **$13.8 million** in Q2 2024[161](index=161&type=chunk) - Net product revenue for LUMRYZ increased **64.2%** to **$68.1 million** in Q2 2025 compared to Q2 2024, driven by patient growth to approximately **3,100** as of June 30, 2025[162](index=162&type=chunk) - The company initiated the REVITALYZ Phase 3 trial for LUMRYZ in Idiopathic Hypersomnia (IH), with the first patient dosed on **July 31, 2024**, and enrollment expected to complete by the end of **2025**[153](index=153&type=chunk)[154](index=154&type=chunk) - Cash, cash equivalents, and marketable securities increased by **$7.8 million** in the first six months of 2025 to **$81.5 million**, supported by **$4.5 million** in cash from operations[160](index=160&type=chunk) [Results of Operations](index=36&type=section&id=2.1%20Results%20of%20Operations) A detailed analysis of the financial results for the three and six months ended June 30, 2025, compared to the same periods in 2024, showing significant revenue growth, slight gross margin decrease, and shifts in R&D and SG&A expenses Gross Profit Analysis - Six Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Net product revenue | $120,640 | $68,682 | $51,958 | 75.7% | | Cost of products sold | $11,943 | $4,310 | $7,633 | 177.1% | | Gross profit | $108,697 | $64,372 | $44,325 | 68.9% | | Gross profit margin | 90% | 94% | - | - | - R&D expenses increased by **$1.5 million (20.9%)** in H1 2025, primarily due to costs for the Phase 3 REVITALYZ clinical trial for LUMRYZ in IH[164](index=164&type=chunk) - SG&A expenses decreased by **$1.8 million (1.9%)** in H1 2025, driven by a **$10.6 million** reduction in legal costs, offsetting increased spending on commercial activities, including higher employee costs (**$5.5M**) and patient/market access costs (**$4.7M**)[166](index=166&type=chunk) [Liquidity and Capital Resources](index=38&type=section&id=2.2%20Liquidity%20and%20Capital%20Resources) The company's liquidity position improved significantly, generating $4.5 million in cash from operations in H1 2025, driven by net income and non-cash adjustments, with management believing existing cash and anticipated revenue are sufficient for the next 12 months Net Cash Flow Summary - Six Months Ended June 30 (in thousands) | Activity | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Operating | $4,465 | $(47,890) | $52,355 | | Investing | $4,063 | $31,937 | $(27,874) | | Financing | $1,672 | $13,913 | $(12,241) | - The company believes its existing cash, cash equivalents, marketable securities, and anticipated cash from LUMRYZ sales provide sufficient capital for at least the next twelve months[175](index=175&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company outlines its exposure to market risks, primarily interest rate, foreign exchange, and inflation, deeming current impacts immaterial but acknowledging potential future effects on operational costs - Interest Rate Risk: A hypothetical **50 basis point** change in interest rates would not materially impact the fair value of the company's securities due to the short-term nature of the portfolio[177](index=177&type=chunk) - Foreign Exchange Risk: Exposure is primarily from one subsidiary with a euro functional currency, where a **10%** change in the euro exchange rate would have an immaterial impact on net income[178](index=178&type=chunk) - Inflation Risk: The company does not believe inflation had a material effect on its results for the period but acknowledges it could affect future costs for clinical trials, commercialization, and labor[180](index=180&type=chunk) [Controls and Procedures](index=40&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of June 30, 2025, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of **June 30, 2025**[181](index=181&type=chunk) - There were no material changes in internal control over financial reporting during the three months ended **June 30, 2025**[182](index=182&type=chunk) [PART II - OTHER INFORMATION](index=40&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) This part covers legal proceedings, updated risk factors, equity sales, and other significant corporate information [Legal Proceedings](index=41&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates by reference the detailed information on the company's ongoing litigation, primarily with Jazz Pharmaceuticals, as disclosed in Note 12 of the financial statements - Information regarding legal proceedings is incorporated by reference from **Note 12: Commitments and Contingencies - Litigation**[184](index=184&type=chunk) [Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors) This section updates the company's risk factors, emphasizing threats from political and trade instability, intense industry competition, and potential changes in tax law - The company faces significant competition for LUMRYZ from authorized generic versions of Jazz's Xyrem and potential future products, including orexin 2 receptor agonists[188](index=188&type=chunk) - Significant political, trade, or regulatory developments, such as tariffs and changes in U.S. federal policy, could have a material adverse effect on operations[186](index=186&type=chunk) - Changes in tax law, including the 'One Big Beautiful Bill Act' signed on **July 4, 2025**, and the OECD's Pillar Two model rules, could adversely affect the company's business and financial condition[191](index=191&type=chunk)[193](index=193&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the reporting period - None[195](index=195&type=chunk) [Other Information](index=42&type=section&id=Item%205.%20Other%20Information) The company entered into a new employment agreement with General Counsel Jerad G. Seurer, effective August 6, 2025, and reported no Rule 10b5-1 trading arrangements adopted or modified by directors or officers during Q2 2025 - A new employment agreement was executed with General Counsel Jerad G. Seurer, providing a **$420,000** base salary and a **45%** target bonus[198](index=198&type=chunk)[199](index=199&type=chunk) - During Q2 2025, no company directors or officers adopted, terminated, or modified a Rule 10b5-1 trading arrangement[201](index=201&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including new employment agreements and officer certifications - Filed exhibits include new employment agreements for Susan Rodriguez (dated **May 1, 2025**) and Jerad Seurer (dated **August 6, 2025**)[202](index=202&type=chunk) - Certifications from the Principal Executive Officer and Principal Financial Officer pursuant to SEC rules and the Sarbanes-Oxley Act were also filed[202](index=202&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40297 N-able, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4069861 (State or other jurisdiction of inco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-Q __________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41027 _______________________________ PERIMETER SOLUTIONS ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39351 Nuvation Bio Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 85-0862255 ( State or other jurisdiction o ...

Exhibit 99.1 On a same station basis for the quarter ended June 30, 2025 net revenue decreased $1.5 million or 6.4% to $27.6 million and station operating expense decreased 6.4% to $21.7 million. Net revenue decreased 4.7% to $52.4 million for the six-month period ended June 30, 2025 compared to $55.0 million for the same period last year. Station operating expense decreased 3.4% for the six-month period to $44.2 million compared to the same period last year. For the six-month period, we had an operating lo ...